Soficitinib is a potent and selective TYK2 inhibitor that is being developed for the treatment of various T-cell related autoimmune disorders. The Current indications under development are ...

The government's plans to ease record crown court backlogs have been described as a "worrying price to pay to improve ...

Summary • Silexion Therapeutics Corp (SLXN) stock increased by 6.7% to $2.56 in pre-market trading following a conference ...

Summary • Profusa, Inc. (PFSA) shares rose 5% in pre-market trading, reaching $0.1600 after a trial update announcement.• The ...

The AES meeting is a cornerstone for the epilepsy community, bringing together science, clinical innovation, and patient advocacy,” said Steven Petrou, chief scientific officer and co-founder of ...

Imviva Biotech, a clinical-stage biotechnology company developing next-generation allogeneic CAR-T cell therapies, today announced that i ...

Two oral, and five poster presentations will showcase the company’s progress in developing allogenic cell therapy candidates for multiple ...

In this video from the American Academy of Ophthalmology meeting, Lejla Vajzovic, MD, FASRS, highlights a presentation on macular telangiectasia type 2.

The latest update is out from Purple Biotech ( (PPBT) ).

The abstract accepted for presentation can be viewed online at the ASH conference website here, and will appear in the November supplemental issue of Blood. Please note that the actual presentation ...

SEYMOUR— To learn more about one of the most bizarre episodes in American history, come to a free presentation on the Salem Witch Trials at 7 p.m. Tuesday, Oct. 28 in the Community Room of the ...

50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met primary and all key secondary endpoints in both ABTECT 1 and ABTECT 2 ...